Weiß Claudia, Stoltenburg Corinna, Bayram Dilan, Funk Julia, Lebek Susanne
SPZ for Chronically Sick Children, Department of Neuropaediatrics, Charité - Berlin University of Medicine, Berlin, Germany.
Center for Musculoskeletal Surgery, Department of Paediatric Orthopaedic Surgery and Neuro-Orthopedics, Charité - Berlin University of Medicine, Berlin, Germany.
J Child Orthop. 2020 Aug 1;14(4):349-352. doi: 10.1302/1863-2548.14.200033.
In the 1980s the first results of an early multilevel contracture release (MLCR) in patients suffering from progressive Duchenne muscular dystrophy (DMD) showed a positive effect on ambulation. Despite the demonstrated positive effects of prolongation of walking this treatment is not part of current guidelines. The aim of our study was to evaluate the effect of MLCR as well as its combination with glucocorticoid (GC) treatment on ambulation.
Data of all boys (n = 86) with DMD treated in our outpatient department were analyzed regarding the treatment and loss of independent ambulation. In all, 23 were treated with GC only, ten were operated on, 21 received GC and underwent MLCR and 32 received neither of the two treatments.
The analysis of the loss of independent ambulation in our cohort showed a comparable extension of the ambulatory period between the GC-treated and MLCR-treated boys (p = 0.008 and p = 0.005, respectively). Furthermore, an additive effect of both therapies was found; patients with DMD who had both treatments were able to walk two years longer than those with only one of the two treatment options (p<0.001).
Standard GC treatment and early MLCR in lower limbs have an independent positive effect on prolongation of ambulation in patients with DMD. In our cohort, the combination of both therapies is significantly more effective than each therapy alone. We suggest both should be offered to all DMD patients eligible.Level of evidence: III.
20世纪80年代,对进行性杜氏肌营养不良症(DMD)患者进行早期多级挛缩松解术(MLCR)的首批结果显示,该手术对步行有积极影响。尽管已证明延长步行时间有积极效果,但这种治疗方法并非现行指南的一部分。我们研究的目的是评估MLCR及其与糖皮质激素(GC)联合治疗对步行的影响。
分析了在我们门诊部接受治疗的所有DMD男孩(n = 86)的数据,内容涉及治疗情况和独立行走能力的丧失情况。其中,23例仅接受GC治疗,10例接受了手术,21例接受GC治疗并进行了MLCR,32例未接受这两种治疗中的任何一种。
对我们队列中独立行走能力丧失情况的分析表明,接受GC治疗的男孩和接受MLCR治疗的男孩在步行期延长方面具有可比性(分别为p = 0.008和p = 0.005)。此外还发现了两种疗法的相加效应;同时接受两种治疗的DMD患者比仅接受两种治疗方案之一的患者能够多行走两年(p<0.001)。
标准GC治疗和早期下肢MLCR对DMD患者步行时间的延长具有独立的积极作用。在我们的队列中,两种疗法联合使用比单独使用每种疗法的效果显著更好。我们建议向所有符合条件的DMD患者提供这两种治疗方法。证据级别:III级。